Primary Care/Hospitalist
RSSArticles
-
Natriuretic Peptide-guided Therapy Does Not Improve Systolic Heart Failure Outcomes
A recent meta-analysis of 11 trials showed a significant reduction in all-cause mortality with natriuretic peptide-guided therapy, although the individual trial results varied substantially.
-
Is a Dabigatran Reversal Agent Effective?
Dabigatran is an attractive oral anticoagulant for patients who demonstrate indications for oral anticoagulation but are at high risk of bleeding.
-
Clinical Briefs
In this section: A better definition for celiac disease; shedding light on a vaccine; and treating asthma.
-
Meropenem and Vaborbactam Injection (Vabomere)
The FDA has approved a new combination antibacterial for the treatment of complicated urinary tract infections.
-
Is a Dabigatran Reversal Agent Effective?
A pragmatic clinical study of idarucizumab for counteracting the effects of the oral anticoagulant dabigatran showed rapid and complete reversal of its effects in patients with major bleeding or urgent surgery, without any adverse safety concerns.
-
Mother Was Right: You Are What You Eat
In a study of simplified enterotypes as prognostic markers for successful body fat loss on two different diets, participants with a greater ratio of Prevotella to Bacteroides appeared more susceptible to lose body fat on diets high in fiber and whole grains.
-
Diet High in Carbohydrates, Not Fats, Drives Mortality
A prospective epidemiological cohort study of people 35-70 years of age in 18 countries showed that a higher intake of carbohydrates increased total mortality, while the intake of fats of all kinds did not. A higher intake of saturated fat reduced stroke mortality.
-
Aberrant Conduction or Ventricular Bigeminy?
How would you interpret the tracing? Are these multifocal (multiform) premature ventricular contractions?
-
Clinical Briefs
In this section: managing diabetes; elective surgery; and nephrolithiasis patients.
-
Tisagenlecleucel Suspension (Kymriah)
Kymriah is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.